Other resolutions: 250 444 pixels | 960 1,707 pixels
#Diabetes #Obesity #GLP1 #HealthcareInnovation #Pharmaceuticals #CardiometabolicHealth To view or add a comment, sign in More Relevant Posts Eli Lilly and Company reported results from ACHIEVE-3, the first head-to-head #Phase3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with #Type2Diabetes
If not addressed, stomach paralysis may lead to malnutrition, dehydration, and blood sugar complications
They are injectable medications prescribed to help people with obesity or type 2 diabetes
doi: 10.1042/CS20171459 166 TessaroFHGAyalaTSMartinsJO
Signs of dehydration or potential kidney problemssuch as persistent vomiting, inability to keep fluids down, decreased urination, or dark-colored urineshould prompt immediate medical attention